Monday, September 14, 2026

Pyongyang’s Outrage: North Korea Slams U.S. for Human Rights Discussions

North Korea condemns US-South Korea talks on human rights, calling it a conspiracy and warning against threats to its sovereignty.

Can Trump Transform North Korea Relations in 2026? Insights from Ex-White House Official

Alex Wong suggests Trump could foster better U.S.-North Korea talks by changing conditions, emphasizing dialogue and pressure for denuclearization.

Will Kim Jong Un Ride the Train or Fly for his Big Trip to China?

Kim Jong Un confirms attendance at China's Victory Day, raising questions about his travel method—train or airplane—amid security concerns.

Tag: Therapeutics

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Revolutionizing Obesity Treatment: Hanmi Pharmaceutical’s Digital Fusion Drug EPPE Launching in 2026

Hanmi Pharmaceutical is developing digital therapeutics by combining obesity treatment 'Efe' with digital technology.

HLB’s Rivoceranib Drug Approval: What the FDA’s VAI Classification Means for Liver Cancer Treatment

HLB's Rivoceranib facility received a VAI classification from the FDA, indicating compliance with GMP standards, aiding drug approval progress.

CARTISTEM vs. Traditional Treatments: What Makes Medipost’s Stem Cell Therapy a Game-Changer?

Medipost to commercialize CARTISTEM in Japan using domestically produced media, enhancing supply chain stability and competitiveness.

ST Pharm Expands Global CDMO Outreach at TIDES USA and ASGCT 2026

ST Pharm showcased its CDMO capabilities at TIDES USA and ASGCT 2026, focusing on nucleic acid therapeutics and strategic partnerships.

Large-Scale Real-World Study Supports Zacubo’s Efficacy and Safety in GERD Treatment

A study shows Onconic Therapeutics' Zacubo significantly improves GERD symptoms in patients unresponsive to existing treatments.

Verismo unveils preclinical data on improved antitumor efficacy and safety of blood cancer CAR-T at AACR

HLB Innovation's SynKIR-310 shows improved antitumor activity and safety in preclinical trials, achieving 100% survival in mice.

Nesuparib: The Game-Changing Cancer Treatment for Small Cell Lung Cancer Revealed at AACR 2026

Onconic Therapeutics reveals Nesuparib's promising preclinical results for small cell lung cancer, outperforming existing treatments significantly.

CG MedTech Acquires Human Tissue Processing Bank: What This Means for the Bio Sector in 2026

CG MedTech acquires a human tissue processing bank, expanding into bio business with ECM-based therapeutics and dental materials.

SK Biopharm Launches New Innovative Epilepsy Treatment Drug, Cenobamate, in China

SK Biopharm's epilepsy drug Cenobamate launches in China, marking a key milestone in its global expansion and commercialization strategy.

Emocog’s Cogthera is Revolutionizing MCI Treatment in 2026

Emocog develops innovative digital therapeutics for mild cognitive impairment, enhancing dementia care through early intervention and AI technology.

Revolutionary CAR-T Treatment SynKIR-310 Outperforms CD19 CAR-T: What This Means for Blood Cancer Patients

Verismo Therapeutics' SynKIR-310 shows superior anti-tumor effects in preclinical studies, promising a safer CAR-T therapy for blood cancers.

Verismo Therapeutics Welcomes FDA Approval Expert Dennis Williams: What This Means for CAR-T Cell Therapy

HLB Innovation appoints Dr. Dennis Williams as VP of Regulatory Affairs at Verismo Therapeutics to enhance global regulatory strategies.

How JNPMEDI Plans to Achieve 250% Revenue Growth in 2026: A Guide for Pharma Innovators

JNPMEDI aims to enhance its global role in drug and medical device development, achieving significant growth and expanding partnerships.

ST Pharm’s Record Growth: How RNA-Based Therapies Are Transforming the CDMO Market in 2026

ST Pharm reports record growth in oligonucleotide CDMO, driven by rising demand for RNA-based treatments for chronic diseases.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.